Literature DB >> 26886523

Statin-Associated Autoimmune Myopathy.

Andrew L Mammen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26886523     DOI： 10.1056/NEJMra1515161

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  80 in total

1.  Statin-induced necrotizing autoimmune myopathy.

Authors:  Syed A Huda; Sanjay Yadava; Sara Kahlown; Muhammad S Farooqi; Stephanie Bryant; Ronald Russo
Journal:  Proc (Bayl Univ Med Cent)       Date:  2020-10-21

2.  Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence.

Authors:  Liam R Brunham; Steven Baker; Andrew Mammen; G B John Mancini; Robert S Rosenson
Journal:  Cardiovasc Res       Date:  2018-07-01       Impact factor: 10.787

Review 3.  A case of statin-associated immune-mediated necrotizing myopathy with atypical biopsy features.

Authors:  Mark M Zaki; Zain M Virk; Diego Lopez; Jenna Klubnick; Jared T Ahrendsen; Hemant Varma; Vasileios Kyttaris; Ilana Abeles
Journal:  Eur J Rheumatol       Date:  2021-01-01

4.  Statin-associated immune-mediated necrotizing myopathy: a retrospective analysis of individual case safety reports from VigiBase.

Authors:  Dirk Essers; Martina Schäublin; Gerd A Kullak-Ublick; Stefan Weiler
Journal:  Eur J Clin Pharmacol       Date:  2018-11-15       Impact factor: 2.953

5.  Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.

Authors:  Makoto Kinoshita; Koutaro Yokote; Hidenori Arai; Mami Iida; Yasushi Ishigaki; Shun Ishibashi; Seiji Umemoto; Genshi Egusa; Hirotoshi Ohmura; Tomonori Okamura; Shinji Kihara; Shinji Koba; Isao Saito; Tetsuo Shoji; Hiroyuki Daida; Kazuhisa Tsukamoto; Juno Deguchi; Seitaro Dohi; Kazushige Dobashi; Hirotoshi Hamaguchi; Masumi Hara; Takafumi Hiro; Sadatoshi Biro; Yoshio Fujioka; Chizuko Maruyama; Yoshihiro Miyamoto; Yoshitaka Murakami; Masayuki Yokode; Hiroshi Yoshida; Hiromi Rakugi; Akihiko Wakatsuki; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2018-08-22       Impact factor: 4.928

6.  New Antilipid Drugs: Do the Known Benefits Justify the Expense?

Authors: 
Journal:  Can J Hosp Pharm       Date:  2016-08-31

7.  More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy.

Authors:  Eleni Tiniakou; Iago Pinal-Fernandez; Thomas E Lloyd; Jemima Albayda; Julie Paik; Jessie L Werner; Cassie A Parks; Livia Casciola-Rosen; Lisa Christopher-Stine; Andrew L Mammen
Journal:  Rheumatology (Oxford)       Date:  2017-05-01       Impact factor: 7.580

Review 8.  Novel Therapeutic Options in Treatment of Idiopathic Inflammatory Myopathies.

Authors:  Namita A Goyal; Tahseen Mozaffar
Journal:  Curr Treat Options Neurol       Date:  2018-07-23       Impact factor: 3.598

Review 9.  Potential Pathogenic Role of Anti-Signal Recognition Protein and Anti-3-hydroxy-3-methylglutaryl-CoA Reductase Antibodies in Immune-Mediated Necrotizing Myopathies.

Authors:  Leandro Ladislau; Louiza Arouche-Delaperche; Yves Allenbach; Olivier Benveniste
Journal:  Curr Rheumatol Rep       Date:  2018-08-03       Impact factor: 4.592

10.  Association of Statin Exposure With Histologically Confirmed Idiopathic Inflammatory Myositis in an Australian Population.

Authors:  Gillian E Caughey; Genevieve M Gabb; Saffron Ronson; Michael Ward; Timothy Beukelman; Catherine L Hill; Vidya Limaye
Journal:  JAMA Intern Med       Date:  2018-09-01       Impact factor: 21.873
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.